LEIOMYOSARCOMA

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This study tests whether the drug Ivonescimab can safely shrink or control advanced leiomyosarcoma, a rare soft-tissue cancer. About 20 adults who have already tried 1-3 prior treatments will receive the drug. The goal is to see if it slows tumor growth with few side effects.

This study is for adults with high-risk soft tissue sarcoma that can be removed by surgery. It tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy, radiation, and surgery can delay the cancer from coming back. About 50 participants will receive the …

This study is for people with a rare, high-risk cancer called retroperitoneal sarcoma. It compares two approaches: getting chemotherapy before surgery versus surgery alone. The goal is to see if the chemo-first approach helps prevent the cancer from coming back. About 250 partici…

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This phase II trial compares the chemotherapy drugs trabectedin and gemcitabine in 100 people with advanced leiomyosarcoma that has worsened after initial treatment. The study aims to see which drug better delays cancer progression. It also includes an observational group for tho…

This early-phase trial is testing a combination of two drugs, gemcitabine and nab-sirolimus, in people with advanced leiomyosarcomas or soft-tissue sarcomas that have lost function in the TSC1 or TSC2 genes. The main goal is to find a safe and tolerable dose. The study plans to e…

This phase 3 trial tests the drug AL3818 (anlotinib) in people with advanced alveolar soft part sarcoma, leiomyosarcoma, or synovial sarcoma. Currently, only patients with alveolar soft part sarcoma are being enrolled. Participants receive AL3818 pills or a standard chemotherapy …

This study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring…

This phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see h…

This study tests whether a personalized 3-week course of proton radiation before surgery for soft tissue sarcoma can reduce long-term side effects compared to standard X-ray radiation. About 110 adults in Norway will receive either proton or X-ray therapy, chosen individually for…

This study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …

This study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers wil…

This study tests whether combining two drugs—ATRA and cemiplimab—can shrink or control advanced leiomyosarcoma that has stopped responding to standard treatments. About 16 adults with metastatic or locally advanced, inoperable leiomyosarcoma will receive ATRA pills for 3 days bef…

This study investigates whether fragments of tumor DNA circulating in the blood can be used to detect and monitor soft tissue sarcoma. Researchers will collect blood and tumor tissue samples from 40 adults with high-risk sarcomas to see if this DNA can serve as a biomarker for ca…

This study is collecting blood and tumor samples from 200 people with metastatic leiomyosarcoma who are starting chemotherapy. Researchers will analyze circulating tumor DNA (ctDNA) and genetic changes to see if they can predict how well the chemotherapy works. Participants also …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study looks at whether a blood test for tumor DNA (ctDNA) and detailed scans can help predict how well chemotherapy works in people with a rare soft tissue cancer called leiomyosarcoma. About 40 participants will give blood samples and have scans before, during, and after tr…